7-(2,2-dimethylpropyl)-6-[(2,4-dioxo-3-propyl-1,3,8-triazaspiro[4.5]dec-8-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile | 501127-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 7-(2,2-dimethylpropyl)-6-[(2,4-dioxo-3-propyl-1,3,8-triazaspiro[4.5]dec-8-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
• 英文别名: 7-(2,2-dimethyl-propyl)-6-(2,4-dioxo-3-propyl-1,3,8-triaza-spiro[4,5]dec-8-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile；7-(2,2-dimethylpropyl)-6-[(2,4-dioxo-3-propyl-1,3,8-triazaspiro[4.5]decan-8-yl)methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile
• CAS: 501127-11-3
• 化学式: C₂₃H₃₁N₇O₂
• 分子量: 437.545
• InChiKey: ROOAZSFNNONQFB-UHFFFAOYSA-N

物化性质

• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7-(2,2-dimethylpropyl)-6-[(2,4-dioxo-3-propyl-1,3,8-triazaspiro[4.5]dec-8-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile 、 sodium;hydride 、 碘甲烷 在 氯化铵 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 silica gel 、 甲醇 、 二氯甲烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以MeOH=25:1 (v/v) and CH2Cl2:MeOH=15:1 (v/v) to give 71 mg of desired product in 34% yield的产率得到7-(2,2-Dimethyl-propyl)-6-(1-methyl-2,4-dioxo-3-propyl-1,3,8-triaza-spiro[4,5]dec-8-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
  参考文献：
  名称：

  Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

  摘要：

  该发明提供了I式化合物或其药学上可接受的盐或酯，其中符号的含义如定义所述，这些化合物是猫hepsin K的抑制剂，并在药学上用于治疗与猫hepsin K有关的疾病和医疗情况，例如各种紊乱，包括炎症，类风湿性关节炎，骨关节炎，骨质疏松和肿瘤。

  公开号：

  US07452886B2
• 作为产物：
  描述：

  6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile 、 3-Propyl-1,3,8-triazaspiro[4.5]decane-2,4-dione 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 生成 7-(2,2-dimethylpropyl)-6-[(2,4-dioxo-3-propyl-1,3,8-triazaspiro[4.5]dec-8-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
  参考文献：
  名称：

  Effect of Cathepsin K Inhibitors on Bone Resorption

  摘要：

  Oil the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.

  DOI：

  10.1021/jm800626a

文献信息

• Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
  申请人：Betschart Claudia

  公开号：US20050054851A1

  公开（公告）日：2005-03-10

  The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供了I式化合物或其药学上可接受的盐或酯，其中符号的含义如定义所述，它们是猫hepsin K的抑制剂，并在药学上用于治疗猫hepsin K参与的疾病和医疗情况，例如各种疾病，包括炎症、类风湿性关节炎、骨关节炎、骨质疏松和肿瘤。
• PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES
  申请人：Novartis AG

  公开号：EP1423391A1

  公开（公告）日：2004-06-02
• US7452886B2
  申请人：——

  公开号：US7452886B2

  公开（公告）日：2008-11-18
• [EN] PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES<br/>[FR] PYRROLOPYRIMIDES EN TANT QU'AGENTS D'INHIBITION DE CYSTEINE PROTEASES
  申请人：NOVARTIS AG

  公开号：WO2003020721A1

  公开（公告）日：2003-03-13

  The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
• Effect of Cathepsin K Inhibitors on Bone Resorption
  作者：Naoki Teno、Keiichi Masuya、Takeru Ehara、Takatoshi Kosaka、Takahiro Miyake、Osamu Irie、Yuko Hitomi、Naoko Matsuura、Ichiro Umemura、Genji Iwasaki、Hiroaki Fukaya、Kazuhiro Toriyama、Noriko Uchiyama、Kazuhiko Nonomura、Ikuo Sugiyama、Motohiko Kometani

  DOI：10.1021/jm800626a

  日期：2008.9.11

  Oil the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.